The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971–983 (1993).
Atwal, R.S. et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16, 2600–2615 (2007).
Kim, M.W., Chelliah, Y., Kim, S.W., Otwinowski, Z. & Bezprozvanny, I. Secondary structure of Huntingtin amino-terminal region. Structure 17, 1205–1212 (2009).
Tam, S. et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 16, 1279–1285 (2009).
Darnell, G., Orgel, J.P., Pahl, R. & Meredith, S.C. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J. Mol. Biol. 374, 688–704 (2007).
Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996).
Martín-Aparicio, E., Avila, J. & Lucas, J.J. Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur. J. Neurosci. 16, 355–359 (2002).
Benn, C.L. et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28, 10720–10733 (2008).
Seong, I.S. et al. Huntingtin facilitates polycomb repressive complex 2. Hum. Mol. Genet. 19, 573–583 (2010).
Godin, J.D. et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 67, 392–406 (2010).
Steffan, J.S. et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100–104 (2004).
Aiken, C.T. et al. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem. 284, 29427–29436 (2009).
Thompson, L.M. et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187, 1083–1099 (2009).
Lecerf, J.M. et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98, 4764–4769 (2001).
Snyder-Keller, A., McLear, J.A., Hathorn, T. & Messer, A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J. Neuropathol. Exp. Neurol. 69, 1078–1085 (2010).
Williamson, T.E., Vitalis, A., Crick, S.L. & Pappu, R.V. Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin. J. Mol. Biol. 396, 1295–1309 (2010).
Colby, D.W., Cassady, J.P., Lin, G.C., Ingram, V.M. & Wittrup, K.D. Stochastic kinetics of intracellular huntingtin aggregate formation. Nat. Chem. Biol. 2, 319–323 (2006).
Thakur, A.K. et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16, 380–389 (2009).
Wetzel, M.K. et al. p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease. Neuron 59, 708–721 (2008).
Gu, X. et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828–840 (2009).
Greenfield, N.J. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1, 2876–2890 (2006).
Schilling, G. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397–407 (1999).
Zhang, H. et al. Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci. 9, 38 (2008).
Bordeaux, J. et al. Antibody validation. Biotechniques 48, 197–209 (2010).
Hoffner, G., Kahlem, P. & Djian, P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J. Cell Sci. 115, 941–948 (2002).
Pagano, M.A. et al. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321, 1040–1044 (2004).
Cozza, G. et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 421, 387–395 (2009).
Burke, J.R. et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. 278, 1450–1456 (2003).
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004).
Truant, R., Atwal, R.S., Desmond, C., Munsie, L. & Tran, T. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 275, 4252–4262 (2008).
Wetzel, R. Nucleation of huntingtin aggregation in cells. Nat. Chem. Biol. 2, 297–298 (2006).
Reina, C.P., Zhong, X. & Pittman, R.N. Proteotoxic stress increases nuclear localization of ataxin-3. Hum. Mol. Genet. 19, 235–249 (2009).
Mueller, T. et al. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 18, 3334–3343 (2009).
Fan, M.M., Zhang, H., Hayden, M.R., Pelech, S.L. & Raymond, L.A. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. J. Neurochem. 104, 790–805 (2008).
Modregger, J., DiProspero, N.A., Charles, V., Tagle, D.A. & Plomann, M. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum. Mol. Genet. 11, 2547–2558 (2002).
Plomann, M. et al. PACSIN, a brain protein that is upregulated upon differentiation into neuronal cells. Eur. J. Biochem. 256, 201–211 (1998).
Di Maira, G., Brustolon, F., Pinna, L.A. & Ruzzene, M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell. Mol. Life Sci. 66, 3363–3373 (2009).
Humbert, S. et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831–837 (2002).
Kageura, T. et al. Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: structural requirements of stilbenes for the activity. Bioorg. Med. Chem. 9, 1887–1893 (2001).
Pierce, J.W. et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272, 21096–21103 (1997).
Shaul, J.D., Farina, A. & Huxford, T. The human IKKβ subunit kinase domain displays CK2-like phosphorylation specificity. Biochem. Biophys. Res. Commun. 374, 592–597 (2008).
McElhinny, J.A., Trushin, S.A., Bren, G.D., Chester, N. & Paya, C.V. Casein kinase II phosphorylates IκBα at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol. Cell. Biol. 16, 899–906 (1996).
Witt, J. et al. Mechanism of PP2A-mediated IKKβ dephosphorylation: a systems biological approach. BMC Syst. Biol. 3, 71 (2009).
Metzler, M. et al. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci. 30, 14318–14329 (2010).
Pardo, R. et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 26, 1635–1645 (2006).
Trushin, S.A., Pennington, K.N., Algeciras-Schimnich, A. & Paya, C.V. Protein kinase C and calcineurin synergize to activate IκB kinase and NF-κB in T lymphocytes. J. Biol. Chem. 274, 22923–22931 (1999).
Bamborough, P. et al. Progress towards the development of anti-inflammatory inhibitors of IKKβ. Curr. Top. Med. Chem. 9, 623–639 (2009).
Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799–2809 (2000).